Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. Journal of Kidney Cancer, [S. l.], v. 12, n. 4, p. 7–18, 2025. DOI: 10.15586/jkcvhl.v12i4.403. Disponível em: https://mail.jkcvhl.com/~jkcvhlco/index.php/jkcvhl/article/view/403. Acesso em: 20 oct. 2025.